Biocraft cefadroxil ANDA approval
Generic version of Bristol-Myers' Ultracef and Duracef 500 mg caps approved Feb. 10. In January, Biocraft had filed suit against Bristol-Myers seeking declaratory judgment invalidating Bristol's patent covering cefadroxil, which reportedly covers the crystalline form of the bulk material and expires in 2004. An ongoing hearing will determine whether Biocraft should be prohibited from marketing prior to a final decision, Biocraft said. The firm said it could start shipping the product before the end of March unless barred by a court order.
You may also be interested in...
Centaur-CytoTools introduces novel topical treatment for diabetic foot ulcers in India, for which they see limited direct competition and hope to change the way the difficult-to-treat diabetes complication is managed. Phase III studies are ongoing in Europe.
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.
Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.